Abstracts / Can J Diabetes 38 (2014) S29eS74 S45

8% fitting DM diagnosis. A total of 64% had a diagnosis of estab-lished DM or potentially newly diagnosed DM or prediabetes.

118

A Cross-Sectional Survey of Cardiometabolic Risk Factors inCanadian Primary Care Patients with Abdominal ObesityDAVID C.W. LAU*y, LAWRENCE A. LEITERy, JACQUES J.G. GENEST JR.y,STEWART B. HARRISy, PETER SELBYy, VALERIE TAYLORy, MAJA BUJAS-BOBANOVICy, JOHN STEWARTy

Calgary, AB; Toronto, ON; Montreal, QC; London, ON; Paris, France;Laval, QC

The objectives of this cross-sectional study were to evaluate theprevalence as well as the management of cardiometabolic riskfactors (CMRFs) in overweight/obese Canadians. Subjects withincreased body mass index (BMI >27 kg/m2 )/waist circumference(WC >94 cm in men, >80 cm in women) were recruited by 468primary care physicians across Canada (37% from Ontario, 28% fromQuebec and 35% from other provinces), and evaluated during asingle clinic visit. In addition, the following risk factors were alsoassessed: hypertension (SBP >130 and/or DBP >80), dysglycemia(IGT or diabetes), low HDL-C (<1 in men or <1.3 mmol/L inwomen), triglycerides>1.7 mmol/L, LDL-C>3.5 mmol/L or>2 withcardiovascular event, and smoking status. A total of 9985 subjectswere included in the analysis: mean age 58 years, M/F (52%/48%),mean BMI 33.2 and 34.0 kg/m2, mean WC 113.2 cm and 106.4 cm,for men and women, respectively. Women had a median of �3CMRFs while men had a median of �4 CMRFs. 70% of the subjectshad additional CMRFs with the following prevalence: high LDL-C(81.9%), hypertriglyceridemia (69.8%), hypertension (67.2%), lowHDL-C (51.6%), high LDL-C + hypertension (63.4%), high LDL-C + lowHDL-C (45.7%), hypertension + lowHDL-C (37.3%), lowHDL-C + highLDL-C + hypertension (36.2%), diabetes (34%), high LDL-C + dys-glycemia (33.0%). Guideline targets for prediabetes, diabetes, dys-lipidemia and hypertension were often not being achieved despitetreatment. CMRFs are more common in overweight/obese peoplewith abdominal obesity in primary care, and requiremore intensivesurveillance and management to reduce their cardiometabolic risk.

119

Cardiometabolic Risk Factors in Canadian Primary Care Patientswith Abdominal Obesity and DiabetesDAVID C.W. LAU*y, LAWRENCE A. LEITERy, JACQUES J.G. GENEST JR.y,STEWART B. HARRISy, PETER SELBYy, VALERIE TAYLORy, MAJA BUJAS-BOBANOVICy, JOHN STEWARTy

Calgary, AB; Toronto, ON; Montreal, QC; London, ON; Paris, France;Laval, QC

This cross-sectional study evaluated the prevalence and themanagement of cardiometabolic risk factors (CMRFs) in over-weight/obese subjects, who were recruited by 468 primary carephysicians across Canada. In addition to BMI >27 kg/m2 or highwaist circumference, the following risk factors were also assessed:hypertension, dysglycemia (IGT or diabetes by CDA criteria), lowHDL-C, triglycerides >1.7 mmol/L, LDL-C >3.5 mmol/L or >2 withcardiovascular event and smoking status. Of a total of 9985 subjectsanalyzed, 3398 (34%) had diabetes, with a higher mean age thannondiabetic subjects (60.5 years vs. 56.5 years). 77% of people withdiabetes were taking oral agents and 18% were treated with insulin,with a mean A1C of 7.13%. More CMRFs were reported in the dia-betes subjects, with an average of 4.6 vs. 2.6. People with diabeteswere 10-fold more likely to have �5 additional CMRFs (59.6% vs.5.6%, respectively), and fewer of them had �2 additional CMRFs(3.1% vs. 44.3%). Hypertriglyceridemia and hypertensionwere morecommon in the diabetes group (90% vs. 59% and 81% vs. 54% innondiabetic subjects, respectively). Coronary artery disease, pe-ripheral artery disease and severe renal impairment were more

common in people with diabetes. A greater proportion of themwere taking statins for dyslipidemia (76% vs. 35%) and antihyper-tensive drugs (78% vs. 50%) even though many were not treated toguidelines target values. In conclusion, CMRFs are much morecommon in overweight/obese peoplewith diabetes in primary care,and require more intensive management to reduce their cardio-vascular disease risk and mortality.

120

Glycemic Efficacy of Canagliflozin (CANA) by Baseline A1C andKnown Duration of Type 2 Diabetes Mellitus (T2DM)LAWRENCE A. LEITER, LAWRENCE BLONDE, JOHN WILDING,SONIA CERDAS, CINDY TONG, JACQUELINE YEE, GARY MEININGERToronto, ON; New Orleans, LA; Liverpool, United Kingdom; San José,Costa Rica; Raritan, NJ

Purpose: This analysis evaluated the effects of CANA versus pla-cebo (PBO) on changes in A1C based on baseline A1C and durationof T2DM.Methods: Pooled data from 4 PBO-controlled phase 3 studies ofpatients with T2DM (n¼2313;mean age, 56.0 years; A1C, 8.0%; BMI,32.1 kg/m2; mean known T2DM duration, 7.3 years) were analyzed.Change in A1C at 26 weeks (last observation carried forward[LOCF]) was evaluated in subgroups by baseline A1C and T2DMduration. Least squares(LS) mean changes (standard error [SE])were calculated and PBO-subtracted differences (95% confidenceinterval [CI]) are reported.Results: CANA 100 and 300 mg were associated with progres-sively greater PBO-subtracted LS mean reductions in A1C asbaseline A1C increased (A1C <8.0%: e0.45% and e0.65%; A1C8.0%e<9.0%: e0.91% and e1.07%; A1C �9.0%: e1.25% and e1.48%respectively). PBO-subtracted A1C reductions with CANA 100and 300 mg were e0.70% and e0.96%, respectively, for patientsin early stages of T2DM (<5 years). In patients with 5e<10 yT2DM duration, PBO-subtracted A1C differences were e0.74 ande0.91% with CANA 100 and 300 mg, respectively; differenceswere e0.74% and e0.85%, respectively, in patients with �10years T2DM duration. Overall, CANA doses were generally welltolerated.Summary: Greater reductions in A1C with CANA were seen inpatients with higher baseline A1C, similar to what has beenobserved with other antihyperglycemic agents.

121

Efficacy of Canagliflozin (CANA) in Patients with Type 2Diabetes Mellitus (T2DM) by Baseline Body Mass Index (BMI)LAWRENCE A. LEITER*, LAWRENCE BLONDE, JOHN WILDING,SONIA CERDAS, CINDY TONGy, JACQUELINE YEEy, GARY MEININGERy

Toronto, ON; New Orleans, LA; Liverpool, UK; San Agustín, Costa Rica;Raritan, NJ

Purpose: This analysis evaluated the effect of CANA versus placebo(PBO) on changes in A1C, body weight and SBP, stratified by base-line BMI.Methods: Pooled data from 4 PBO-controlled phase 3 studiesevaluated changes in A1C, body weight and SBP at 26 weeks(last observation carried forward [LOCF]) by subgroups bybaseline BMI (<25 kg/m2, 25 to <30 kg/m2, 30 to <35 kg/m2,and �35 kg/m2 ). Least squares (LS) mean changes werecalculated within each subgroup, and PBO-subtracted differ-ences in LS mean changes (95% confidence interval [CI]) arereported.Results: At week 26 (LOCF), LS mean reductions from baseline inA1C levels, body weight and SBP were greater with CANA versusPBO regardless of baseline BMI, with CANA 300 mg generallyproviding greater reductions in all 3 parameters than CANA 100 mg